Rosa Klotz

University Hospital Heidelberg
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Background Complete surgical resection (R0 resection) is crucial for overall and disease-free survival in patients with pancreatic cancer undergoing curative surgery. The radical antegrade modular pancreatosplenectomy (RAMPS) procedure was developed to increase achievement of R0 resection margins for tumour resections of the pancreatic body and tail. By extending the posterior dissection plane, a more radical surgical resection can be achieved, as this is the most frequent site of positive margins in conventional left pancreatectomy. RAMPS includes a standardized lymph node dissection and early control of the splenic vessels. Feasibility and safety have already been demonstrated and retrospective studies have shown promising results regarding higher proportions of R0 resection and lymph node counts. To date, high-quality evidence from randomized clinical trials investigating the oncological benefit of RAMPS (that is, resection margin status, disease-free and overall survival) for this patient cohort is lacking. Methods The RAMPS trial is a multicentre, randomized clinical, patient and assessor-blinded, confirmatory, superiority trial. In all, 122 patients with an indication for left pancreatectomy due to malignancy of the pancreatic body or tail will be required in each study arm to achieve 80% power at a significance level of 0.025; patients will be randomized to either the RAMPS approach or conventional left pancreatectomy in a 1 : 1 ratio. Patients will be recruited over a 30-month enrolment period. The primary outcome will be the achievement of R0 resections. Secondary outcomes include survival and surgical, functional, and patient-reported outcomes with a 3-year follow-up. Conclusion The primary objective of the RAMPS trial is to demonstrate the superiority of the RAMPS approach over standard left pancreatectomy in improving the achievement of R0 resection and, consequently, long-term oncological patient outcomes. RAMPS could be established as the new surgical standard for tumour resection in patients with pancreatic cancer in the body or tail of the pancreas. Registration number: DRKS00033031 (https://www.bfarm.de/EN/BfArM/Tasks/German-Clinical-Trials-Register/_node.html).

Year:

2025

BACKGROUND Recently surgical data recorders comparable to flight data recorders also known as black boxes in the aviation industry have been developed to improve patient safety and performance in surgery. These devices allow for unique insights in the operating room by providing new data capture capabilities. No systematic review has been carried out to evaluate the areas of application of surgical data recorders to date. OBJECTIVE This systematic review and single-arm meta-analysis aimed to assess which aspects of the operating theatre environment surgical data recorders are used for. And to make a preliminary assessment of the quantifiable data that can be collected compared to traditional collection methods. METHODS The systematic review followed the PRISMA guidelines. Medline, Embase and Web of Science databases were lastly systematically searched for papers that focused on a clinical use case for surgical data recorders on February 10th 2025. Not relevant papers in particular papers focusing on implementation of surgical data recorders were excluded. Title, abstract and full-text screening were completed to identify relevant articles. The included studies were analyzed descriptively using data extraction forms. Where possible, quantifiable data was also analyzed. Risk of bias was assessed using the ROBINS-E tool. RESULTS 70 studies were screened and a total of 17 studies were included. Ten of the 17 studies had a low overall risk of bias; however, confounding, selection bias, small sample sizes, short study periods, and potential Hawthorne effects were notable limitations. Only 2 studies were assessed to have publication bias. Use cases could be grouped into four categories: economic, safety, behaviour in the OR and technical skill assessment. A single-arm meta-analysis focusing on adverse events and distractions in the operating theatre could be conducted, demonstrating accurate reporting of distractions in line with the existing literature. CONCLUSIONS Surgical data recorders provide an unobstructed view of various aspects of the operating theatre. Most published papers present preliminary studies on surgical data recorders, indicating the potential for further, larger-scale studies with enhanced methodological quality. CLINICALTRIAL PROSPERO, CRD42024527164, Registered on April 1st, 2024.

Year:

2025

Objective: To provide a composite endpoint in pancreatic surgery. Background: Single endpoints in prospective and randomized studies have become impractical due to their low frequency and the marginal benefit of new interventions. Methods: Data from prospective studies were used to develop (n=1273) and validate (n=544) a composite endpoint based on postoperative pancreatic fistula, postpancreatectomy hemorrhage, as well as reoperation and reinterventions. All patients had pancreatectomies of different extents. The association of the developed PAncreatic surgery Composite Endpoint (PACE) with prolonged length of hospital stay >75th percentile and mortality was assessed. A single-institution database was used for external validation (n=2666). Sample size calculations were made for single outcomes and the composite endpoint. Results: In the internal validation cohort, the PACE demonstrated an area under the curve of 78.0%, a sensitivity of 90.4%, and a specificity of 67.6% in predicting a prolonged length of hospital stay. In the external cohort, the area under the curve was 76.9%, a sensitivity of 73.8%, and a specificity of 80.1%. The 90-day mortality rate was significantly different for patients with a positive versus a negative PACE both in the development and internal validation cohort (5.1% vs 0.9%; P < 0.001), as well as in the external validation cohort (8.5% vs 1.2%, P < 0.001). The PACE enabled sample size reductions of up to 80.5% compared to single outcomes. Conclusions: The PACE performed well in predicting prolonged hospital stays and can be used as a standardized and clinically relevant endpoint for future prospective trials enabling lower sample sizes and therefore improved feasibility compared to single outcome parameters.

Year:

2024

Year:

2023

Collaborators (6)

Markus W. Büchler

Heidelberg University

GERMANY
View details

Thomas Pausch

Senior Physician and Head of Digital Transformation and Data Science in Surgery

University Hospital Heidelberg

GERMANY
View details

Thilo Hackert

University Hospital Heidelberg

GERMANY
View details

Felix J Hüttner

-

GERMANY
View details

Pascal Probst

Heidelberg University

GERMANY
View details

Hannes G Kenngott

University Hospital Heidelberg

GERMANY
View details